Advertisement
Singapore markets closed
  • Straits Times Index

    3,224.01
    -27.70 (-0.85%)
     
  • Nikkei

    40,369.44
    +201.37 (+0.50%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Bitcoin USD

    69,999.74
    -582.75 (-0.83%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • FTSE Bursa Malaysia

    1,536.07
    +5.47 (+0.36%)
     
  • Jakarta Composite Index

    7,288.81
    -21.28 (-0.29%)
     
  • PSE Index

    6,903.53
    +5.36 (+0.08%)
     

Accuray Banks on Acquisition & Partnership Amid Competition

On Mar 27, we issued an updated research report on Accuray Inc. ARAY. While this Zacks Rank #3 (Hold) is focused on acquisitions and partnerships, stiff competition is a major concern.

The buyouts of TomoTherapy and Morphormics in the past have helped Accuray expand its product offerings and capabilities. Meanwhile, the collaboration with Christie InnoMed will help its products gain better visibility in Canada.

Accuray recently announced an agreement with the Neuro Spinal Hospital in Dubai, UAE. Per the agreement, Neuro Spinal Hospital will acquire the company’s proprietary medical systems consisting of a CyberKnife M6 System and a Radixact System.

 

 

ADVERTISEMENT

The tie-ups with Premier and Amerinet are expected to help the company gain significant traction in hospitals and oncology centers. 

On the flip side, Accuray is exposed to intense competition in the radiation oncology market, which is characterized by rapid technological changes. The company competes with the likes of Varian Medical, Elekta AB, Mitsubishi Heavy Industries, ViewRay and BrainLAB AG in this market.

Accuray’s top line is highly dependent on CyberKnife and TomoTherapy systems sales. However, both the systems require high capital expenditure, which is a deterrent for healthcare providers.

Price Performance Lacks Luster

The company has had an unimpressive run on the bourses of late. A glimpse at the recent price performance reveals that its shares have lost 11.7% over the past month, comparing unfavorably with the industry’s decline of 0.6%. We believe cutthroat competition and weak international sales have led to the downside.

Key Picks

Some better-ranked stocks in the broader medical sector are Bio-Rad Laboratories BIO, athenahealth, Inc. ATHN and Edwards Lifesciences Corporation EW.

Bio-Rad Laboratories sports a Zacks Rank of 1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. The company has a long-term expected earnings growth rate of 20%.

athenahealth is a Zacks #1 Ranked player. The company has a long-term expected earnings growth rate of 21.5%.

Edwards Lifesciences has a long-term expected earnings growth rate of 15.1%. The stock has a Zacks Rank of 2 (Buy).

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
athenahealth, Inc. (ATHN) : Free Stock Analysis Report
 
Accuray Incorporated (ARAY) : Free Stock Analysis Report
 
Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report
 
Bio-Rad Laboratories, Inc. (BIO) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.